its up-regulation in the blood cells of patients may disturb normal T-cell function via hyper-activation of CD8+ memory T cells.
Bardet-Biedl syndrome 5 (BBS5) is one of 18 causative genes (BBS1-18) for an autosomal recessive ciliopathy disorder with eye, kidney, and heart defects 31 . The BBSome (a complex of seven BBS proteins) localizes at or near the primary cilium and the centrosome, associates with the centriolar satellite protein CEP131 via BBS4, and plays a role in transporting ciliary membrane proteins 32 . BBS5, which localizes along the axonemes of rods and cones, is phosphorylated by protein kinase C to regulate the translocation of arrestin1 (Arr1) between the inner and outer segments according to the light conditions in photoreceptor cells 33 . Eye site defects observed in BD patients may be a consequence of improper translocation of Arr1 due to overexpression of BBS5.
Bile acid CoA:amino acid N-acyltransferase (BAAT) is involved in bile acid metabolism by catalyzing the hydrolysis of long-and very long-chain saturated acyl-CoAs into the free fatty acid and coenzyme A, and also conjugates glycine to these acyl-CoAs.
Defective mutations in BAAT are involved in familial hypercholanemia.
Cysteinyl leukotrienes (CysLT) mediate bronchoconstriction and play important roles in the development of asthma; CysLT receptor 2 (CysLTR2), a G-protein-coupled seven-transmembrane receptor for CysLTs, is expressed in multiple cell types including macrophages, vascular smooth muscle, brain, and B and T lymphocytes, in which it regulates allergic inflammation 34, 35 . Notably, sequence variants of the CYSLTR2 gene are associated with aspirin-intolerant asthma 36 . Given that augmented expression of CysLTR1 in nasal inflammatory leukocytes is also related to aspirin-intolerant asthma 37 , elevated
CysLTR2 expression may be involved in inflammation of various tissues in BD patients.
By contrast, no report to date has suggested any clinical relevance of several other up-regulated genes, including those encoding neuromedin U (NMU), guanylate cyclase 2F (GUCY2F), pyrophosphatase 2 (PPA2), and phosphoglucomutase 5 (PGM5). Therefore, it remains elusive why these genes were up-regulated in PBMCs of BD patients.
Down-regulated genes: mRNA levels of interferon (IFN) alpha-inducible protein 27 (IFI27), olfactomedin 4 (OLFM4), phosphatidylinositol N-acetylglucosaminyltransferase subunit C (PIGC), and membrane-spanning 4-domains, subfamily A, member 2 (MS4A2) genes were down-regulated by >˗3.0-fold in both male and female BD patients relative to healthy volunteers (Fig. 1b, Supplementary Fig. S2b However, scatter plot showed that average values of these genes were almost unaltered (Supplementary Fig. S5 ). Thus, we conclude that these down-regulated genes are not important.
Pathway analysis
Ficolin-1 (FCN1) functions as a recognition molecule in the complement system. We Analysis of other immune-related pathways revealed no notable genes, except for a modest up-regulation of defensin beta 1 (DEFB1) and mitogen-activated protein (MAP) kinase kinase 6 (MAP2K6) in many BD patients (Supplementary Fig. S7 ). DEFB1 encodes an antimicrobial peptide that is a basic component of human innate immunity; DEFB1 plays a protective role against allergies and infection, and is up-regulated by inflammatory or microbial stimuli 44 . Given that MAP2K6 plays a role in inflammatory diseases via phosphorylation-mediated activation of p38 MAP kinase in response to inflammatory cytokines, and MAP2K6-deficient mice exhibit reduced severity of arthritis 45 , it is reasonable to speculate that its activation may influence the arthritis-related inflammatory abnormalities in some BD patients.
Supplementary Materials and Methods

Human subjects and ethical considerations
Forty-three BD patients were enrolled at Osaka University Hospital (BD1-41 plus the mother and daughter of BD20) between 2001 and 2009; the genders and ages of BD patients are provided in Figure S1 . The study was reviewed and approved by the Research Ethics Committee of Osaka University, and written informed consent was obtained from all participants. The diagnosis of BD was established according to standard criteria proposed by the Japan BD Research Committee; actual study methods were carried out in accordance with the approved guidelines. Serum samples were obtained from patients regardless of their symptoms and level of disease activity/inactivity.
Target selection and sequencing
Exome sequencing was conducted on four DNA samples from patients with familial BD: patient BD47 and her aunt (BD20), grandmother (BD26), and mother (BD50). Genomic DNA was extracted from PBMC using the PAXgene Blood DNA Kit (QIAGEN), sheared into 150-200 bp fragments, and used to make a library for multiplexed paired-end sequencing (Illumina). The resultant library was hybridized to biotinylated cRNA oligonucleotide baits from the SureSelect Human All Exon 50Mb kit (Agilent Technologies) for exome capture. Targeted sequences were purified using magnetic beads, amplified, and sequenced on an Illumina HiSeq2000 platform in paired-end 101 bp configuration. The raw sequence data were submitted to the NCBI SRA database under accession No. SRP059981
(NCBI BioProject PRJNA288379).
Mapping and SNV/indel calling
The quality of DNA reads was checked using software developed in-house. Adapter sequences and sequences of inadequate quality were removed. After quality control, reads were mapped to the reference human genome (UCSC Genome Browser, hg19) using BWA (ver. 0.5.9). Mapping results were corrected using Picard (ver. 1.49) for removal of duplicates and genome analysis toolkit (GATK; ver. 1.1-31-gdc8398e) for local alignment and quality score recalibration. SNV and insertion/deletion (indel) calls were performed on pooled reads from four samples using GATK, and filtered to coordinate with variant quality 
Preparation of RNA and DNA microarray analysis
RNA was prepared from PBMCs using the PAXgene Blood RNA Kit (QIAGEN 
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